Table 1.
Patient characteristics.
| n or median | % or range | |
|---|---|---|
| Patients | 65 | |
| Clinical characteristics | ||
| Age at brain metastases diagnosis (years) | Median 50 | (27-71) |
| ECOG at brain metastases diagnosis | ||
| 0-1 | 41 | 63.1% |
| 2-4 | 24 | 36.9% |
| Brain metastases at diagnosis | ||
| No | 59 | 90.8% |
| Yes | 6 | 9.2% |
| Neurologic Symptoms | ||
| No | 20 | 30.8% |
| Yes | 45 | 69.2% |
| Largest metastasis tumor size (cm) | 2.8 | 0.8-5.5 |
| Total brain metastases volume (cc) | 15 | 0.35-90.8 |
| Number of metastases | 2 | 1-26 |
| Initial Treatment characteristics | ||
| System treatment + radiotherapy | 28 | 43.1% |
| System treatment + surgery | 7 | 10.8% |
| System treatment without local treatment |
14 | 21.5% |
| Radiotherapy alone | 11 | 16.9% |
| Surgery alone | 5 | 7.7% |
| Radiotherapy approach | ||
| SRS+WBRT | 38 | 58.5% |
| SRS | 23 | 35.4% |
| WBRT | 4 | 6.2% |
| Upfront Surgery | ||
| No | 53 | 81.5% |
| Yes | 12 | 18.5% |
| Her2 targeted agents | 52 | 80% |
| Monoclonal antibody (Trastuzumab or Pertulumab) |
44 | 67.8% |
| TKI(Lapatinib/Pyrotinib) | 1 | 1.5% |
| Both | 7 | 10.8% |